Economic Impact
Despite the pandemic, University of Florida researchers conducted record amounts of research in 2020 and companies born of UF research continued to bring billions of dollars and thousands of jobs into the state.
Tampa Company Developing Cancer Vaccines Could Receive Grant To Research Cervical Cancer Vaccine
UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a Tampa-based company that has been researching and developing a vaccine for certain types of skin cancers, could be soon receiving a grant to begin research on a cervical cancer treatment for underprivileged women.
SARS-CoV-2 Spike Protein Licensed by Oragenics From the NIH Demonstrates Protective Immunity in Mice
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announces that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National Institutes of Health (“NIH”) and licensed by the Company demonstrates protective immunity in immunized mice challenged with mouse-adapted SARS-CoV-2 virus.
JoTo PR Disruptors New Client, Neobiosis, Revolutionizing Cellular Therapy Field, Healthcare
Offering the potential to revolutionize healthcare, a new regenerative medicine firm, Neobiosis, is launching at UF Innovate | Sid Martin Biotech in Alachua, Fla. Moving beyond disease management, regenerative medicine aims to harness and redirect the body’s natural ability to repair itself. This kind of disruptive thinking perfectly aligns with the philosophy of JOTO PR Disruptors, a public relations agency, and it is why they signed the new, cutting-edge R&D scientists.
Odyssey Group International’s Planned Acquisition of Concussion Drug from Prevacus, Inc. Enhances Delivery Capabilities with Nasal Therapeutic
Odyssey Group International is circulating a video to better define its drug candidate PRV-002, a therapeutic compound drug to treat concussion (mild traumatic brain injury (mTBI), from UF Innovate | Sid Martin Biotech alum Prevacus Inc. Odyssey is expected to acquire PRV-002 by the end of February.
Skin Cancer Vaccine Developed by Tampa Company Enters Phase 1 of Clinical Trial
UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc. completed its first-in-human phase one trial in cutaneous melanoma at Moffitt Cancer Center within the past year and has now moved into studying patients in earlier stages of skin cancers.
Research Underway To Treat COVID-19 Long Hauler Syndrome
In this article, UF Innovate | Sid Martin Biotech resident client Neobiosis founder Ian White explains how his company is using regenerative medicine to develop products to treat coronavirus long hauler syndrome. (Note: the University of Florida Innovate Center mentioned in the story should be UF Innovate | Sid Martin Biotech.)
New Resident Client at Sid Martin Biotech to Pave Way for Post-COVID Therapy, Regenerative Medicine Research
The inflammation COVID-19 patients suffer during and post-COVID-19 infection (AKA "Post-COVID Syndrome") will be one of many focuses of a new resident client that recently joined the UF Innovate | Sid Martin Biotech, the world-recognized leader in biotechnology incubation. Neobiosis, which produces regenerative tissues, cells, and extracellular vesicles for research and clinical trials to help the body heal itself—without surgery—will operate a laboratory at the biotech center, located in Alachua.
Abbott Blood Test To Evaluate Mild Concussions Wins FDA Clearance
Doctors soon will have a new way to evaluate patients with concussions: a rapid blood test made by Abbott Laboratories that has been cleared by the U.S. Food and Drug Administration. It’s an advancement that could eliminate the need for some patients to get costly CT scans and the radiation exposure that accompanies them.
Manipulating Milestones in Pandemic Times with AGTC’s Sue Washer
The COVID-19 pandemic continues to disrupt biopharma clinical trials, especially those conducted with at-risk patient populations. From patient recruitment to data collection, clinical trials execution became considerably more challenging in 2020. On this episode of The Business Of Biotech, UF startup and UF Innovate | Sid Martin Biotech graduate AGTC CEO Sue Washer gives us a behind-the-scenes look at the creative measures her company took to serve a geographically dispersed clinical patient population and ensure her company met clinical milestones.
